Absolute and relative outcomes of psychotherapies for eight mental disorders: a systematic review and meta‐analysis

作者：Pim Cuijpers, Clara Miguel, Markéta Čihařová, Mathias Harrer, Djordje Basic, Ioana A. Cristea, Nino de Ponti, Ellen Driessen, Jessica L. Hamblen, Sadie E. Larsen, Minoo Matbouriahi, Davide Papola, Darin Pauley, Constantin Yves Plessen, Rory A. Pfund, Kim Setkowski, Paula P. Schnurr, Wouter van Ballegooijen, Yingying Wang, Heleen M. Riper, Annemieke van Straten, Marit Sijbrandij, Toshi A. Furukawa, Eirini Karyotaki · 发表于：World Psychiatry · 年份：2024 · DOI：10.1002/wps.21203 · 被引用次数：161 · 研究领域：Treatment of Major Depression、Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes、Psychosomatic Disorders and Their Treatments

Psychotherapies are first-line treatments for most mental disorders, but their absolute outcomes (i.e., response and remission rates) are not well studied, despite the relevance of such information for health care users, providers and policy makers. We aimed to examine absolute and relative outcomes of psychotherapies across eight mental disorders: major depressive disorder (MDD), social anxiety disorder, panic disorder, generalized anxiety disorder (GAD), specific phobia, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and borderline personality disorder (BPD). We used a series of living systematic reviews included in the Metapsy initiative (www.metapsy.org), with a common strategy for literature search, inclusion of studies and extraction of data, and a common format for the analyses. Literature search was conducted in major bibliographical databases (PubMed, PsycINFO, Embase, and the Cochrane Register of Controlled Trials) up to January 1, 2023. We included randomized controlled trials comparing psychotherapies for any of the eight mental disorders, established by a diagnostic interview, with a control group (waitlist, care-as-usual, or pill placebo). We conducted random-effects model pairwise meta-analyses. The main outcome was the absolute rate of response (at least 50% symptom reduction between baseline and post-test) in the treatment and control conditions. Secondary outcomes included the relative risk (RR) of response, and the number needed...